Walking Fish Therapeutics, Inc.

Walking Fish Therapeutics develops a broad B cell platform designed to harness the immune system for therapeutic benefit. This technology addresses multiple areas, including oncology, regenerative medicine, autoimmune diseases, and the production of recombinant antibodies, leveraging B cells' natural capabilities. The company's approach centers on activating or modulating the immune response to treat complex conditions.

The company was founded by Rustem (Rusty) F. Williams, M.D., Ph.D., who previously held leadership roles at Five Prime Therapeutics. Dr. Williams launched Walking Fish Therapeutics with the insight that B cells represent a versatile and powerful modality for therapeutic intervention, aiming to translate this novel cell therapy into clinical applications for various diseases.

The platform ultimately aims to serve patients battling severe conditions by advancing B cell therapies. Walking Fish Therapeutics' vision centers on accelerating the development of these versatile B cell modalities to transform treatment paradigms for conditions ranging from cancer and autoimmune disorders to regenerative medicine and enzyme replacement, aspiring to make a significant impact on patient care.

High-Level Overview

Walking Fish Therapeutics, Inc. was a biotechnology company that engineered B cells to act as protein factories for treating serious diseases including cancer, autoimmune disorders, regenerative medicine needs, and rare diseases like Fabry disease.[1][2][3] It targeted oncology (e.g., solid tumors), autoimmune conditions, infectious diseases, and deficiencies by developing cell-based therapies such as WFT-1, WFT-2, and WFX-003, all in preclinical stages before shutdown.[1][3][5] The company raised $73 million across two Series A rounds ($50M in 2021, $23M in 2022) but ceased operations in May 2024 after a lead investor withdrew from a planned Series B, just as it sought clinical trial clearance for its Fabry program.[1]

Headquartered in South San Francisco, California, Walking Fish served patients with unmet needs in immuno-oncology and regenerative medicine, drawing inspiration from the axolotl's regenerative abilities to create potent, tissue-targeted B cell therapies.[2][3] Despite early momentum with an oversubscribed Series A and lab expansion, the firm shut down abruptly, auctioning equipment shortly after.[1]

Origin Story

Founded in 2019 (some sources note 2018), Walking Fish Therapeutics emerged from alumni of Five Prime Therapeutics, led by CEO Rusty Williams, MD, PhD.[1][2][4] Williams, with expertise in protein therapeutics and immuno-oncology, drove the vision for B cell engineering as a novel cell therapy modality.[3][4] The idea built on deep B cell biology knowledge to transform these cells into long-lasting protein and antibody factories, inspired by natural regenerative processes like those in the axolotl.[3]

Early traction included a $50M Series A in September 2021, followed by a $23M extension in February 2022, enabling a new 22,000 sq ft headquarters and lab in South San Francisco.[1][2] The team expanded leadership, appointing Georgia Erbez as COO, and advanced a pipeline toward clinical trials in oncology, rare diseases, and regenerative medicine.[2] Pivotal moments included platform advancements and preclinical candidates like WFX-001 for Fabry disease.[1][5]

Core Differentiators

• B Cell Engineering Platform: Pioneered engineered B cells (including CAR-B cells) as selective, local protein/antibody factories for antitumor responses, regenerative medicine, and autoimmune treatments, with advances in editing technologies and B cell biology.[1][2][3][6]
• Broad Therapeutic Pipeline: Preclinical programs spanned oncology (WFT-2/WFX-003 for solid tumors), rare diseases (WFX-001/WFT-3 for Fabry and regeneration, targeting GLA stimulants and cell replacements), and antibody production.[3][5]
• Tissue Targeting and Persistence: Emphasized potent, durable therapies for unmet needs in cancer, autoimmunity, and deficiencies, potentially avoiding muscle loss in treatments unlike some blockbusters.[1][3]
• Expert Team and Facilities: Backed by Five Prime veterans; expanded to world-class labs for rapid progression toward clinic.[2][4]

Role in the Broader Tech Landscape

Walking Fish rode the wave of next-generation cell therapies, shifting from T cell-focused CAR-T to B cell engineering for more persistent, tunable protein delivery in oncology and regeneration.[1][3] Timing aligned with surging biotech investment in immuno-oncology and rare diseases post-2020, fueled by mRNA successes and demand for targeted biologics amid autoimmune epidemics.[1][2] Market forces like high unmet needs in solid tumors and Fabry disease favored its platform, which promised localized responses without broad toxicity.[3][5]

Though short-lived, it influenced the ecosystem by validating B cells as a modality—paving for competitors like Immusoft—and highlighting funding risks in preclinical biotech, where investor pullouts can end promising ventures.[1] Its auction and IP potential underscore asset recycling in a consolidating sector.

Quick Take & Future Outlook

Walking Fish's shutdown in May 2024 marks a cautionary tale of biotech volatility: strong science and $73M raised couldn't overcome Series B hurdles amid a cooling funding climate.[1] Its B cell platform assets, including preclinical candidates, were likely acquired post-auction, potentially fueling ongoing efforts in oncology and rare diseases by acquirers or rivals.[1][5]

Trends like AI-driven protein design and combination cell therapies will shape successors, amplifying B cell potential for durable, off-the-shelf treatments. Walking Fish's legacy endures in proving the concept, reminding investors that timing and partnerships define survival in high-stakes biotech.